Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 856

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 856
---
 following persons to the senior management in the sense of an advisory vote: Mr. Ronen Twito Prof. Michel Revel Mr. Kfir Malkandov Mr. Ariel Revel Dr. Eric Konofal Detailed information on the proposed senior management is provided in the invitation. 12. Compensation for the Members of the Board of Directors and Executive Management 12.1. Approval of the Compensation for the Board of Directors The board proposes to adjust the compensation for the Board of Directors, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF 200,000 for the fixed compensation of the Board of Directors. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF 350,000 for the compensation of Board of Directors and the board proposes the participation in the purchase of a run-off insurance policy for the members of the Board of Directors, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2. Approval of the Compensation for the Executive Officers The board proposes to adjust the compensation for the Company’s executive officers, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF 494,000 for the fixed compensation and a new maximum aggregate amount of CHF 2,206,000 for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF 991,000 for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run-off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of the financial year 2025 and the financial year 2026. 13. Approval of Contingent Value Rights (CVR) Agreement on an Advisory Basis The board proposes to approve the CVR Agreement in the sense of an advisory vote. The company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset. 14. Approval of Option and RSU Conversion on an Advisory Basis The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at